PMID- 30214717
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2046-2069 (Print)
IS  - 2046-2069 (Electronic)
IS  - 2046-2069 (Linking)
VI  - 8
IP  - 9
DP  - 2018
TI  - Synthesis of water-degradable silica nanoparticles from carbamate-containing 
      bridged silsesquioxane precursor.
PG  - 4914-4920
LID - 10.1039/C7RA12377A [doi]
AB  - Silica nanoparticles (SNPs) are attractive for applications for the delivery of 
      drugs and as imaging agents due to their ease of synthesis and scale up, robust 
      structure, and controllable size and composition. Degradability is one important 
      factor that limits biomedical applications of SNPs. With this in mind, we 
      designed, prepared and characterized novel hydrolysable organosilica 
      nanoparticles (ICPTES-Sorbitol SNPs). These particles were prepared by 
      co-condensation of tetraethoxysilane with a bridged sorbitol-based silsesquioxane 
      precursor containing carbamate linkages. The non-porous spherical ICPTES-Sorbitol 
      SNPs became porous after they were placed in an aqueous environment as a result 
      of the hydrolysis of carbamate bonds and were completely degraded upon prolonged 
      exposure to water. The rate of degradation depended on the pH of the solution, 
      with nanoparticles degrading slower at pH 2 than at pH 4 or pH 7. The degradation 
      was demonstrated by transmission electron microscopy, nitrogen desorption 
      analysis and solution analytical techniques such as ICP-MS and molybdenum blue 
      assay, which was also used to follow the dissolution of ICPTES-Sorbitol SNPs.
FAU - Gao, Zhe
AU  - Gao Z
AD  - Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
FAU - Hadipour Moghaddam, Seyyed Pouya
AU  - Hadipour Moghaddam SP
AD  - Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, 
      University of Utah.
AD  - Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah.
FAU - Ghandehari, Hamidreza
AU  - Ghandehari H
AD  - Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, 
      University of Utah.
AD  - Utah Center for Nanomedicine, Nano Institute of Utah, University of Utah.
AD  - Department of Bioengineering, University of Utah.
FAU - Zharov, Ilya
AU  - Zharov I
AD  - Department of Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
LA  - eng
GR  - R01 ES024681/ES/NIEHS NIH HHS/United States
PT  - Journal Article
DEP - 20180129
PL  - England
TA  - RSC Adv
JT  - RSC advances
JID - 101581657
PMC - PMC6133298
MID - NIHMS938851
COIS- Conflicts of interest There are no conflicts to declare.
EDAT- 2018/09/15 06:00
MHDA- 2018/09/15 06:01
PMCR- 2018/01/29
CRDT- 2018/09/15 06:00
PHST- 2018/09/15 06:00 [entrez]
PHST- 2018/09/15 06:00 [pubmed]
PHST- 2018/09/15 06:01 [medline]
PHST- 2018/01/29 00:00 [pmc-release]
AID - c7ra12377a [pii]
AID - 10.1039/C7RA12377A [doi]
PST - ppublish
SO  - RSC Adv. 2018;8(9):4914-4920. doi: 10.1039/C7RA12377A. Epub 2018 Jan 29.